Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial

• DOI: 10.1161/circulationaha.124.069215
• Publication Date: 2024-09-04T09:00:32Z
• Authors: Xiongjing Jiang; Felix Mahfoud; Wei Li; Hui Dong; Jing Yu; Shuhua Yu; Xiaoping Chen; Peijian Wang; Zhiqiang Li; Lucas Lauder; Zhifang Wang; Zheng Ji; Yifei Dong; Bing Han; Zhiming Zhu; Yulin Chen; Jianzhong Xu; Xingsheng Zhao; Weidong Fan; Wen Xie; Brad Hubbard; Xi Hu; Kazuomi Kario; Runlin Gao
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Original Research Articles

BACKGROUND: Renal denervation (RDN) can lower blood pressure (BP) in patients with hypertension in both the presence and absence of medication. This is a sham-controlled trial investigating the safety and efficacy of RDN in China.

METHODS: This prospective, multicenter, randomized, patient- and outcome-assessor-blinded, sham-controlled trial investigated radiofrequency RDN in patients with hypertension on standardized triple antihypertensive therapy. Eligible patients were randomized 1:1 to undergo RDN using a multi-electrode radiofrequency catheter (Iberis; Shanghai Angiocare Medical Technology, Shanghai, China) or a sham procedure. The primary efficacy outcome was the between-group difference in baseline-adjusted change in mean 24-hour ambulatory systolic BP from randomization to 6 months.

RESULTS: Of 217 randomized patients (mean age, 45.3±10.2 years; 21% female), 107 were randomized to RDN and 110 were randomized to sham control. At 6 months, there was a greater reduction in 24-hour systolic BP in the RDN (−13.0±12.1 mm Hg) compared with the sham control group (−3.0±13.0 mm Hg; baseline-adjusted between-group difference, −9.4 mm Hg [95% CI, −12.8 to −5.9]; P<0.001). Compared with sham, 24-hour diastolic BP was lowered by −5.0 mm Hg ([95% CI, −7.5 to −2.4]; P<0.001) 6 months after RDN, and office systolic and diastolic BP was lowered by −6.4 mm Hg ([95% CI, −10.5 to −2.3]; P=0.003) and −5.1 mm Hg ([95% CI, −8.2 to −2.0]; P=0.001), respectively. One patient in the RDN group experienced an access site complication (hematoma), which resolved without sequelae. No other major device- or procedure-related safety events occurred through follow-up.

CONCLUSIONS: In this trial of Chinese patients with uncontrolled hypertension on a standardized triple pharmacotherapy, RDN was safe and reduced ambulatory and office BP at 6 months compared with sham.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02901704.